Background: Rhinovirus infections do not only cause common colds, but may also trigger severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Even though rhinoviruses have been the focus of extensive drug development efforts in the past, an anti-rhinoviral drug still has to make it to the market. In the past, the viral capsid protein VP1 has been shown to be an important target for the development of antiviral molecules. Furthermore, many different chemical scaffolds appear to possess the properties that are required to inhibit virus replication by this mechanism of action. I-6602, an analogue of the rhinovirus inhibitor pirodavir, was previously identified as a potent inhibitor of rhinovirus infection. Here, we describe the antiviral activity of its analogue ca603, a molecule with a modified linker structure, and corroborate its mechanism of action as a capsid binder.
Body of text
The genus Enterovirus comprises several human pathogens with a substantial clinical impact on society like poliovirus (PV), rhinoviruses (HRV) and enterovirus 71 (EV71) [1] . Rhinoviruses cause common colds in healthy people but may trigger exacerbations in patients with asthma and COPD [2, 3] . Vaccination against rhinovirus infection is not yet feasible due to the large number of serotypes. Treatment with small-molecule inhibitors therefore seems to be the best possible option to lower the burden of this disease. To date, the rhinoviral capsid and protease are the best characterized antiviral targets. However, a drug has still to be approved for clinical use [1] . In the past, several early-stage rhinovirus inhibitors, referred to as capsid binders, were discovered. Pleconaril, pirodavir and vapendavir are the most extensively studied capsid binders (Fig. 1) . In 2002, the New Drug Application for pleconaril (Schering-Plough) as drug against the common cold was rejected by the FDA, mainly because of safety reasons [4, 5] . Pirodavir (Janssen Pharmaceutica) inhibits in vitro the replication of both HRV-A,-B and, to a lesser extend, that of other enteroviruses [6] . Prophylactic treatment with pirodavir reduced the frequency of experimental rhinovirus infections and subsequent clinical colds only when the drug was administered intranasally six times a day [7] . Oral delivery of the esterderivate pirodavir is not feasible given the fact that it rapidly hydrolyses to an inactive acid. No reduction of clinical symptoms was observed in the subsequent therapeutic trial with experimental rhinovirus infection. Although pirodavir treatment of naturally acquired rhinovirus infections significantly reduced virus shedding during the treatment period, no positive outcome on the clinical signs and respiratory symptoms was observed [8] . Furthermore, in all trials, pirodavir treatment was associated with an unpleasant taste and the more frequent presence of blood in the nasal mucus. Vapendavir (Biota Holdings), a benzisoxazole analogue of pirodavir, is currently in clinical development for the treatment of rhinovirus-induced asthma exacerbations [9] . In the past, we explored the antiviral activity of a panel of pirodavir analogues with modifications of the central hydrocarbon chain [10, 11] . Here, we report on the particular characteristics of the antiviral activity and mode of action of a novel and the until now most potent and least toxic analogue in this series (Fig. 1) . Compound ca603 has been designed based on the structure of I-6602 and was synthesized at ASM Company (Burgwedel, Germany).
The antiviral activity of ca603 was assessed in a multicycle, virus-cell-based cytopathic effect (CPE) reduction assay in HeLa cells [12] . The compound proved to be active against HRV strains from both the HRV-A (HRV09, HRV29, HRV85 and HRV89) and HRV-B group (HRV14, HRV70 and HRV86) ( Table 1 ) with a 50 % effective concentrations (EC 50 's) ranging from 0.01 μM to 15 μM. Although ca603 exerted in vitro antiviral activity against EV71, PV1 and echovirus 11 (ECHO11), the compound was not able to induce complete protection against virusinduced CPE at non-toxic concentrations (Table 1) .
Early-stage inhibitors like pleconaril and pirodavir are only able to prevent virus replication when added prior to, or at the time of infection in a time-of-drug addition assay. Akin to pleconaril, ca603 lost its inhibitory activity when added after infection, indicating that ca603 acts, as expected, at an early stage in the rhinovirus replication cycle (Fig. 2) .
Next, the antiviral potency of ca603 was assessed on the replication of two earlier-reported pleconaril-resistant EV-B ECHO11 2.5 ± 1.6 1.7 ± 0.4
Antiviral activity was determined in a CPE reduction assay with MTS read-out. EC 50 = median 50 % effective concentration ± MAD from dose response curves set up from ≥ four experiments of which at least two independent. * = 100 % inhibition of virus-induced cytopathic effect can be achieved with this compound (as determined by microscopic inspection). CC 50 HeLa = 153 ± 19 μM; CC 50 BGM = 171 ± 16 μM; CC 50 RD = 221 ± 28 µM HRV14 variants [9] . Both virus mutants were generated by site-directed mutagenesis (Quikchange-Stratagene, primer sequences available on request) in a HRV14 infectious clone (kindly provided by D. Blaas, University of Vienna, Austria). Viruses derived from this infectious clone (IC) are designated as HRV14 IC . The single mutant HRV14 IC VP1_A150V proved to be 10-and 40-fold less sensitive to ca603 and pleconaril, respectively ( Table 2 ). Both ca603 and pleconaril proved also markely less active (12-and 28-fold, respectively) against the double mutant HRV14 IC VP1_A150V_E276K. Rhinoviruses are sensitive to thermal stress. However, interaction with a capsid binder can stabilize the virion and increase the temperature at which heat inactivation occurs. We assessed the effect of ca603 on two HRV14 IC strains in a thermostability assay (Fig. 3) . HRV14 IC wildtype or HRV14 IC VP1_A150V_E276K were incubated with a fixed concentration of ca603 (1 μM) or pleconaril (10 μM) for 15 min at 37°C, 2 min at temperatures ranging from 37-57°C (Lightcycler 96, Roche), followed by a rapid cool down to 4°C. Infectious viral loads were subsequently quantified by end-point titration. Both HRV14 IC wild-type and HRV14 IC VP1_A150V_E276K were equally sensitive to heat-inactivation (Fig. 3a) : gradual loss of infectivity is observed by increasing the temperature to 57°C. In the presence of ca603 and pleconaril, heat-inactivation of HRV14 IC wild-type shifted to higher temperatures, suggesting that both compounds stabilize the viral capsid and protect the virus from heat degradation (Fig. 3b ). Both compounds were not able to preserve the infectivity of HRV14 IC VP1_A150V_E276K to the same extent, indicating loss of interaction with either compound (Fig. 3c) . Some residual protection was still observed, which is in agreement with the fact that the reverse-engineered pleconaril-resistant HRV strain is only partially resistant to the antiviral activity of the compounds.
Sequence alignment of the VP1 residues reported to constitute the hydrophobic pocket within the capsid were constructed with the use of CLC sequence viewer (Qiagen). For the HRV-B strains in the test panel, no satisfying explanation could be derived from this Activity was determined in a CPE reduction assay with MTS read-out. EC 50 = median 50 % effective concentration ± MAD. Data are in duplicate from three independent assays. RR = relative resistance (EC 50 of mutated strain / EC 50 of wild-type). *p < 0.0001, **p < 0.001 Fig. 3 Effect of ca603 and pleconaril on heat-inactivation of HRV14. a HRV14 IC wild-type and HRV14 IC VP1_A150V_E276K are equally inactivated by increasing temperatures. b Both ca603 and pleconaril were able to rescue wild-type virus from heat-inactivation. c The mutant VP1_A15V_E276K shows reduced protection from heat-inactivation in the presence of ca603 and pleconaril. Data are in duplicate from two independent assays (mean ± STD) alignment that explains the moderate activity (>2 μM) against HRV42 and HRV70 compared to the potent activity (<2 μM) against HRV14 and HRV86 (Additional file 1: Figure S1 ). Also for the panel of HRV-A strains, no pattern of residues in the hydrophobic pocket could explain the difference in activity (from none against HRV2 and HRV63, moderate against HRV9 and HRV 85, to potent activity against HRV29 and HRV 89) (Additional file 2: Figure S2 ). The full alignment of HRV-A VP1 proteins revealed an alanine on position 176 (HRV02, FG loop) for the naturally compound-resistant strains, while a serine or threonine was detected for the strains against which moderate activity was observed, and a proline in the most susceptible strains (Fig. 4) . The cross-resistance and thermostabilizing studies indicate that the antiviral effect of ca603 is due to a pleconaril-like mechanism of action, i.e. acting as a capsid binder. The pleconaril/HRV14 capsid protein cocrystal structure (PDB id 1NCQ) [13] was used to study the binding mode of ca603. The Plants-proposed [14] ca603 docking pose well resembled the binding mode that was reported for pleconaril with the two derivatives sharing many key interactions. In particular for ca603, we observed that 1) the oxazole ring was stabilized by hydrophobic interactions with Y197 and L106; 2) the alkyl chain formed extensive van der Waals contacts with I104, V188 and V191; 3) the aryl ring established π-interactions with Y152 and Y128; and 4) the ethoxycarbonyl function made hydrophobic interactions mainly with F186 and P174 (Fig. 5) . For a better understanding of how the observed mutations induce resistance, the interaction of the compound was also investigated in the 
